The price of Lynparza can vary depending on the dosage, formulation, and geographic location. For example, a 30-count bottle of 100mg Lynparza tablets in the United States can cost around $12,000 to $15,000 [1]. Similarly, a 30-count bottle of 150mg Lynparza tablets may range from $14,000 to $17,000 [1].
How much does Lynparza cost without insurance?
Without insurance, the out-of-pocket cost for Lynparza can be substantial, often falling within the range of $12,000 to $17,000 per month for a 30-day supply, depending on the specific dosage and pharmacy [1].
Are there patient assistance programs for Lynparza?
Yes, pharmaceutical companies often provide patient assistance programs. For Lynparza, the manufacturer may offer programs like the Lynparza Savings Card, which could reduce out-of-pocket costs for eligible commercially insured patients [2]. Details on eligibility and savings can typically be found through the drug’s official website or patient support services.
When does Lynparza's patent expire?
The patent expiry dates for Lynparza are subject to ongoing developments and can be complex, involving multiple patents covering the drug and its uses [3]. Information on patent status and potential expiry can be tracked through resources like DrugPatentWatch.com [3].
How does Lynparza's price compare to other similar cancer drugs?
The pricing of Lynparza is generally in line with other targeted therapy cancer drugs. These medications, particularly those for rare or specific genetic mutations in cancer, often carry high price tags due to the extensive research, development, and clinical trials required. Direct comparisons would involve looking at the cost per treatment cycle or per year for other PARP inhibitors or similar targeted therapies, which also frequently cost thousands of dollars per month [1].
What factors influence the price of Lynparza?
Several factors contribute to the price of Lynparza. These include the significant investment in research and development, the costs associated with clinical trials and regulatory approval, manufacturing expenses, and the drug's demonstrated efficacy in treating specific types of cancer. Additionally, market demand and patent exclusivity play a role in pricing strategies [3].